Announcement on Changing Signatory Certified Public Accountant
Filed with SSE · · 2 pages · Chinese
Earlier from RemeGen
- Earnings Preannouncement for 2025
- Announcement on Vesting Results of Relevant Rights in the Related Vesting Period of the 2022 and 2023 A-share Restricted Stock Incentive Plans and Shares Listing
- Announcement on Completion of Initial Share Repurchase and Implementation of Share Repurchase Plan
- Announcement on Adjusting Upper Limit of Shares Repurchase Price
- Announcement on Signing a Licensing Agreement with AbbVie
Later from RemeGen
- Announcement on Voluntary Disclosure of Approval of Marketing Application for Vedicizumab the Treatment of HER2-Low Expressing Breast Cancer with Liver Metastasis
- 2025 Annual Report
- Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by Dual-antibody ADC Drug RC288 for Injection
- Announcement on Voluntary Disclosure of Approval of Marketing Application for Vedicizumab as the First-line Treatment for HER2-Low Expressing Urothelial Carcinoma
- Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference
Follow RemeGen into a list and get an email when it puts out news.
Follow RemeGen